June 1, 2017
Navican, an Intermountain Healthcare company, recently signed an agreement to deploy a precision health informatics solution that will allow hospitals and health systems worldwide to access the sophisticated services of Intermountain’s successful precision medicine program in a “turn-key” manner. The new services, that will be made available through Navican, are aimed at improving outcomes for late stage cancer patients and will offer specialized programs with expert guidance for both oncologists and patients.
The new solution will leverage Navican’s TheraMap Precision Cancer CareTM services and Philips IntelliSpace Genomics platform that integrates large-scale genomic analysis with extensive contextual clinical patient data and that is built to implement precision medicine programs at the point of care. The Philips platform seamlessly integrates Illumina’s next-generation sequencing technologies.
“Despite major technological advances in tumor sequencing capabilities and laboratories, gaps remain between these advanced diagnostics and actually getting patients onto the appropriate therapeutic paths,” says Lincoln Nadauld, MD, PhD, executive director of Intermountain Precision Genomics. “Through this joint approach we are bringing together the latest technologies with the aim to provide community hospitals and treatment centers worldwide with the opportunity to implement Intermountain’s best practice in precision medicine into their everyday care practices.”
